Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidivarin - GW Pharmaceuticals

Drug Profile

Cannabidivarin - GW Pharmaceuticals

Alternative Names: CBDV; CBDV - GW Pharmaceuticals; GWP-42006

Latest Information Update: 28 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GW Pharmaceuticals
  • Developer Charite - Universitatsmedizin Berlin; GW Pharmaceuticals; Montefiore Medical Center
  • Class Analgesics; Antiepileptic drugs; Behavioural disorder therapies; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autistic disorder; Neuropathic pain; Partial epilepsies; Pervasive child development disorders; Prader-Willi syndrome; Rett syndrome
  • No development reported Epilepsy

Most Recent Events

  • 28 Sep 2021 No recent reports of development identified for clinical-Phase-Unknown development in Epilepsy in USA
  • 05 May 2021 GW Pharmaceuticals has been acquired by Jazz Pharmaceuticals plc
  • 12 May 2020 Phase-II clinical trials in Prader-Willi syndrome (In children, In adolescents, In adults) in USA (unspecified route) (NCT03848481)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top